ProQR Therapeutics N.V. (Nasdaq: PRQR) announced earlier that clinical study PQ-010-002, a proof-of-concept study of nasal potential difference (NPD), demonstrated ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE